Abbott Laboratories (ABT) : Hochman Cole Investment Advisors scooped up 215 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 11, 2016. The investment management firm now holds a total of 32,790 shares of Abbott Laboratories which is valued at $1,423,414.Abbott Laboratories makes up approximately 1.20% of Hochman Cole Investment Advisors’s portfolio.
Abbott Laboratories closed down -0.1 points or -0.23% at $43.41 with 36,20,361 shares getting traded on Friday. Post opening the session at $43.53, the shares hit an intraday low of $43.18 and an intraday high of $43.548 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Other Hedge Funds, Including , Central Bank Trust Co reduced its stake in ABT by selling 265 shares or 7.67% in the most recent quarter. The Hedge Fund company now holds 3,192 shares of ABT which is valued at $138,565. Abbott Laboratories makes up approx 0.04% of Central Bank Trust Co’s portfolio.Creative Planning reduced its stake in ABT by selling 15,712 shares or 9.2% in the most recent quarter. The Hedge Fund company now holds 155,008 shares of ABT which is valued at $6,584,740. Abbott Laboratories makes up approx 0.05% of Creative Planning’s portfolio.Eagle Asset Management Inc boosted its stake in ABT in the latest quarter, The investment management firm added 25,081 additional shares and now holds a total of 1,778,201 shares of Abbott Laboratories which is valued at $75,537,978. Abbott Laboratories makes up approx 0.53% of Eagle Asset Management Inc’s portfolio.Burns J W Co Incny reduced its stake in ABT by selling 700 shares or 3.25% in the most recent quarter. The Hedge Fund company now holds 20,865 shares of ABT which is valued at $886,345. Abbott Laboratories makes up approx 0.28% of Burns J W Co Incny’s portfolio.Fruth Investment Management boosted its stake in ABT in the latest quarter, The investment management firm added 41 additional shares and now holds a total of 41,375 shares of Abbott Laboratories which is valued at $1,757,610. Abbott Laboratories makes up approx 0.89% of Fruth Investment Management’s portfolio.
On the company’s financial health, Abbott Laboratories reported $0.62 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $0.61. The company had revenue of $5188.00 million for the quarter, compared to analysts expectations of $5254.57 million. The company’s revenue was down -3.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.71 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Company shares were Reiterated by RBC Capital Mkts on Apr 11, 2016 to “Outperform”, Firm has raised the Price Target to $ 48 from a previous price target of $45 .Shares were Reiterated by RBC Capital Mkts on Jan 29, 2016 to “Outperform” and Lowered the Price Target to $ 45 from a previous price target of $51 .
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.